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This study is done to evaluate the effect of spleen tyrosine kinase inhibitor (BAY61-3606), cyclin-dependent kinase inhibitor (CDKi),
and sodium butyrate (Na-Bu) on the level and phosphorylation of p53 protein and its binding to murine double minute 2 (MDM2)
homologue in human vestibular schwannomas (VS). Primary cultures of the tumor tissues were treated individually with optimum
concentrations of these small molecules in vitro. The results indicate modulation of p53 protein status and its binding ability to
MDM2 in treated samples as compared to the untreated control. The three individual treatments reduced the level of total p53
protein. These treatments also decreased Ser392 and Ser15 phosphorylated p53 in tumor samples of young patients and Ser315
phosphorylated p53 in old patients. Basal level of Thr55 phosphorylated p53 protein was present in all VS samples and it remained
unchanged after treatments. The p53 protein from untreated VS samples showed reduced affinity to MDM2 binding in vitro and it
increased significantly after treatments. The MDM2/p53 ratio increased approximately 3-fold in the treated VS tumor samples as
compared to the control.The differential p53 protein phosphorylation status perhaps could play an important role in VS tumor cell
death due to these treatments that we reported previously.
1. Introduction
The human vestibular schwannomas (VS) are benign tumors
of the vestibular branch of the 8th cranial nerve. Bilateral VS
tumors are mostly familial in nature, also known as neurofi-
bromatosis type 2 (NF2) and as opposed to unilateral tumors
which are generally sporadic. The onset age of familial forms
of these tumors is earlier than that of the sporadic forms.
These tumors cause high morbidity and also cause hearing
loss, nausea, vertigo, tinnitus and facial paralysis, and hydro-
cephalus. Mortality rates are low due to this tumor. However,
a higher rate of mortality is associated with secondary
malignant tumors including gliomas andmeningiomas [1, 2].
The p53 protein is an important cellular component with
numerous key cellular functions [3, 4]. One of its functions
involves its ability to bind to DNA and regulate transcription
and in turn regulate a variety of cellular processes such as cell-
cycle, apoptosis, DNA repair, aging, and senescence [5–8]. It
also regulates a variety of cellular signals upon DNA damage,
oncogenic activation, telomere erosion, change in cellular
contact and adhesion, and hypoxia [5, 7, 8]. The p53 protein
undergoes posttranslational modifications (PTMs) and one
such importantmodification is phosphorylation [9–11]. It has
an array of serine/threonine phosphorylation sites that spans
the entire protein but the majority of them are found in the
N and C terminal regulatory regions [12]. This protein is
phosphorylated at 13 serine residues and 5 threonine residues.
Ten of these phosphorylations occur in the amino terminal
trans-activation domain, 1 occurs in the tetramerisation
domain, 1 occurs in the proline-rich domain, 3 occur in the
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DNA binding domain, and 3 occur in the carboxy terminal
regulatory domain [10].The site-specific p53 phosphorylation
is one of the important PTMswhich affects itsmany functions
including its function as a tumor suppressor [10, 13–17]. The
current study is undertaken to evaluate the effect of small
molecules on the p53 phosphorylation and its correlation to
VS tumor cell survival in vitro.
Cyclin/CDK complexes have important role in cellular
signaling as well as cell proliferation [18]. The spleen tyro-
sine kinase (Syk) is involved in the signaling pathways in
hematopoietic cells and is suggested to be a part of signaling
in nonhematopoietic cell types as well [19, 20]. BAY 61-3606
is a known inhibitor of Syk and previous reports have shown
its anti-inflammatory effects in vitro and in vivo [21]. Na-Bu
and other butyric acid derivatives have differentiating and
antiproliferative effect in colonic epithelium [22, 23] and it
is also a known inhibitor of histone deacetylase (HDAC)
[24]. Kinases have important role in normal cell division
and differentiation and altered kinase activities have been
implicated in cancer development and metastasis. Therefore,
kinase inhibitors are one of the important targets among
cancer therapeutics [25, 26].
In this study we have analysed the effect of BAY 61-3606,
CDK inhibitor (CDKi), and Na-Bu on the level and site-spe-
cific phosphorylation of p53 protein in human VS tumors in
vitro. In addition, effect of these treatments on the binding
affinity of MDM2 to the p53 protein was also analysed. The
results were compared between the untreated controls and
the treated ones. Our results show that modulation of p53
level, its site-specific phosphorylation, and its binding affinity
to MDM2 by these inhibitors could affect VS tumor cell
survival/death in vitro.
2. Methods
2.1. VS Tumor Tissue and Primary Culture. This study was
approved by the National Institute of Mental Health and
Neuro Sciences (NIMHANS, Bangalore, India) human ethics
committee which is in accordance with Indian Council of
Medical Research (ICMR, India) ethical guidelines for bi-
omedical research on human subjects (2000). Informed
consent was obtained from all patients prior to the collection
of tissue samples. Only the patients with VS tumor were
included in this study. Patients with other medical conditions
such as diabetes and heart diseases and the patients who
are taking prescription medications for other ailments were
excluded from this study. A total of 20 fresh VS tumor tissues
were collected from the NIMHANS Neurosurgery Depart-
ment operation theater. Ten of these samples were from
patients belonging to 35 years or younger and the remaining
10 were from older patients of above 35 years of age. The
experiments were done in triplicate with each tumor tissue.
The cell culture media, antibiotic, and the serum were
obtained from Sigma-Aldrich, St. Louis, MO, USA. The pri-
mary VS tumor culture was established as described previ-
ously [27, 28]. Briefly, the fresh VS tumor tissues were col-
lected immediately after surgery, washed extensively in phos-
phate buffered saline (PBS), and minced into small pieces.
No collagenase or trypsin treatments which are generally
employed to release loose cells from solid tissues were applied
in our experiments as they are known to disrupt the VS
tumor tissue or tumor cell integrity. Therefore, the VS tumor
tissues used in this study retained most biological properties
such as cell-cell contact, cell integrity, and to some extent
tumor cell microenvironment as they existed in the patients
in vivo. The tumor tissue pieces were placed in DMEM
supplemented with 10% glucose. The DMEM also consisted
of 10% fetal bovine serum (FBS), 100 units/mL penicillin and
100 𝜇g/mL streptomycin. The tumor tissues were tweezed
with forceps, minced with a sharp blade and loose tumor cells
were separated during this process. These cells and tissues
were then cultured in 35mm Petri dishes (Sigma-Aldrich, St.
Louis, MO) and incubated in a humidified atmosphere of 5%
CO
2
and 95% air at 37∘C. The untreated control and Na-Bu,
CDKi, and BAY 61-3606 treated samples were processed for
Western blots. The time of addition of the small molecules
was taken as “zero” hour. Two tumor samples were used for
time-course experiment to standardize the optimum time
point. One of these samples was from a young patient of 26
years and the other was from a 55-year-old patient. The same
two tumor samples were also used for immunoprecipitation
followed byWestern blot analysis. A total of 20 tumor samples
were treated for 48 h with the individual small molecules and
used for Western blot analysis.
2.2. WI38 Cells. The normal human lung fibroblast cell line
WI38 was obtained from the National Center for Cell Science
(NCCS, Pune, India). This cell line was originally obtained
from American Type Culture Collection (ATCC, USA). It
is then distributed to other labs for research purpose only.
The cells were propagated at 37∘C with 5% CO
2
in a 95%
humidified incubator as described previously [13, 14]. The
cells were fed with DMEM (Sigma-Aldrich, St. Louis, MO,
USA) containing 10% fetal bovine serum (FBS) and propa-
gated to approximately 70 to 80% confluency in 100mm cell
culture dishes in presence of penicillin (100U/mL) and strep-
tomycin (100 𝜇g/mL). The plates containing the cells were
washed thrice with phosphate buffered saline (PBS) and lysed
with Tri reagent (Sigma-Aldrich, St. Louis, MO, USA). The
protein was extracted according to the protocol supplied by
Sigma-Aldrich and the concentration was estimated using
spectrophotometer at 280 nm. The protein lysate from the
untreated VS tumor samples was used as internal controls. In
addition, the WI38 protein was used as an additional control
in the Western blot and immunoprecipitation analyses.
2.3. Na-Bu, CDKi, and BAY 61-3606 Treatments. Na-Bu,
CDKi (2,4-diamino-5-oxo-pyrimidine hydrochloride), and
BAY 61-3606 (2-[[7-(3,4-dimethoxyphenyl)imidazole[1,2-c]
pyrimidin-5-yl] amino]pyridine-3-carboxamide hydro-
chloride) were obtained from Sigma-Aldrich, St. Louis, MO,
USA. The stock solutions were prepared in water and the
treatments were done as described previously [27, 28]. Briefly,
twenty-four hours after seeding the VS tumor tissues to the
Petri plates, one set of plates was left untreated and used as
control, and the others were treated only once with Na-Bu,
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CDKi, or BAY 61-3606 at a final concentration of 2mM [22],
5 nM [26], and 10 nM [21], respectively. The small molecules
solubilized in water were directly added to the Petri plates
containing VS tumor tissues [27, 28]. For the time-course
experiment two tumor samples, one from 26-year-old and
the other from 55- year-old patients, were treated for 24, 48,
and 72 hours and processed after treatment. However, the
Western analysis for the time course experiment was done
thrice; the average values were calculated and plotted in
histograms.
2.4.Western Blotting. Qualitative and quantitative analysis of
the p53 protein in the untreated and treated tumor samples
were done by Western blotting as previously described [27,
28]. Briefly, the tumor samples were washed thrice in PBS,
resuspended in 500 𝜇L of lysis buffer, and disrupted using
Polytron tissue homogenizer (Kinematica AG, Switzerland),
clarified by centrifugation, and the supernatant was trans-
ferred to a fresh Eppendorf tube. One hundred fifty micro-
grams of protein from each lysate was separated on 7.5%
SDS-PAGE gels and transferred to PVDFmembrane (Sigma-
Aldrich, St. Louis, MO). A 9% SDS-PAGE gel was used to
detect the 11 kDa S-100A2 protein [27, 28]. High-molecular
weight prestained marker (broad range markers, sc-2361;
Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used
as molecular weight standard. All the gels were run in
duplicate, and one set was incubated with total p53 antibody
or phospho-specific p53 antibodies. The other membrane
was probed with 𝛾-tubulin antibody (clone GTU-88, T5326;
Sigma-Aldrich, St. Louis, MO, USA) which acted as an inter-
nal loading control. The primary antibody for p53 (sc-
126, 1 : 500) and the phospho-specific p53 antibodies for
Ser392 (sc-7997, 1 : 500), Ser315 (sc-17106-R, 1 : 500), Ser15
(sc-54277-R, 1 : 500), and Thr55 (sc-12904-R, 1 : 500) and
the corresponding AP-conjugated secondary antibodies were
purchased from Santa Cruz Biotechnology, Santa Cruz,
CA, USA. These membranes were washed, incubated with
appropriate secondary antibodies, and developed with one
step NBT-BCIP (Sigma-Aldrich, St. Louis, MO, USA).
2.5. Immunoprecipitation. Immunoprecipitation protocol
was as described previously [16, 29] and as prescribed
by Santa Cruz Biotechnology, Santa Cruz, CA, USA. The
MDM2 (WH0004193M1-100UG) and 𝛾-tubulin primary
antibodies and the corresponding secondary antibodies
were obtained from Sigma Aldrich, St. Louis, MO, USA. The
protein A agarose (sc-2001) was obtained from Santa Cruz
Biotechnology, SantaCruz, CA,USA. Briefly, 200𝜇Lof tumor
tissue lysates was incubated with 0.1 𝜇g of p53 primary
antibody (mentioned under Western blot) for 2 hours at
4∘C. Ten microliters of protein A conjugated agarose was
added to this mix and incubated on rocker at 4∘C for an
additional 2 hours.This mixture was centrifuged at 3000 rpm
for 30 seconds at 4∘C, washed twice in PBS, resuspended in
2x electrophoresis sample buffer, boiled and loaded on to
SDS-PAGE gels, and processed as described under Western
blot. The membranes were probed individually with either
MDM2 or p53 antibody.
2.6. Specificity of Control and p53 Antibodies. The phospho-
specific antibodies are known to recognise the p53 protein
only when the specific sites are phosphorylated and they
do not cross react with unphosphorylated forms or other
phosphorylated forms of p53 protein. The p53 antibody and
the phospho-specific antibodies recognised 53 kDa protein
bands.TheMDM2 antibody recognised amajor 90 kDa band
and two minor bands one slightly above and the other below
the major band. The 𝛾-tubulin antibody recognised a 48 kDa
protein band.
2.7. Quantitation. The levels of protein bands were estimated
by measuring the band intensities using Bio-Rad (Bio-Rad,
Australia) quantity 1 software for all the samples individually,
and these values were normalized to the corresponding
control 48 kDa 𝛾-tubulin bands from the same samples
[27, 28]. The levels of p53 protein in WI38 cell line were
taken as 1.0 and the levels in untreated controls samples
were calculated based on their intensities and reported as
level of increase [13, 14]. The protein levels in the treated
samples were calculated for each tumor tissue based on the
corresponding untreated control and reported as level of
decrease in the treated samples [13, 14]. Thus the p53 level
in the WI38 cell line was used only to estimate the protein
levels in untreated control samples and then the comparisons
were done only between the untreated control and treated
samples. The MDM2/p53 ratio for the WI38 cell line was
taken as 1.0.Thep53 andMDM2protein band intensitieswere
measured from the treated and untreated samples and the
ratios of MDM2/p53 were calculated using the ratio of WI38
as standard.
2.8. Statistical Analysis. Statistical analysis of the data was
performed using Statistical Package for Social Sciences
(SPSS) version 18.0. Paired t-test was performed for all the
values. Generalized linear model repeated measures analysis
of variance (RMANOVA) one-way classification was used.
The overall levels of p53 protein and phosphorylated p53
proteins between the untreated control and Na-Bu, CDKi,
and BAY 61-3606 treated samples were analysed for statistical
significance [27, 28]. A 𝑃 value < 0.05 was considered as
statistically significant.
3. Results
3.1. Effect of Na-Bu, CDKi, and BAY 61-3606 Treatments on
the Level of p53 Protein. The untreated VS tumor sample had
increased level of p53 protein as compared to the basal level
found in WI38 cell line. There was an overall decrease in the
level of p53 protein in the treated VS samples as compared
to the untreated control. Na-Bu, CDKi, and BAY 61-3606
treatments lead to a 2- to 3-fold decrease in the level of
p53 protein as compared to the untreated control samples
and it was statistically significant with a 𝑃 value < 0.05. The
decreased level of p53 protein was observed in all the VS
tumor samples 48 hours after treatment (Figures 1(a) and
1(b)).
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Figure 1: (a) Representative Western blot analysis of the effect of Na-Bu, CDKi, and BAY 61-3606 on the level of p53 protein in VS tumor
sample in vitro 48 hours after treatment. The 53 kDa p53 band and the 48 kDa 𝛾-tubulin bands are marked as indicated on the left. TheWI38
was used as an additional control. VS18 is a tumor sample from a 55-year-old female patient; VS1 is a tumor sample from 26-year-old male
patient. The lanes are as marked above: UT, untreated; Na-Bu, sodium butyrate treated; CDKi, CDKi treated; BAY 61, BAY 61-3606 treated.
(b) Histogram of the combined data fromVS tumor samples showing level of p53 and various phosphorylated forms of p53 proteins 48 hours
after treatment. Total p53 andThr55 bars represent data for 20 VS tumor samples. Ser392 (Y) and Ser392 (O) represent combined data from
10 young (35 years or younger) and 10 old (above 35 years old) patients, respectively. Ser315 (Y) and Ser315 (O) represent the same young and
old patients as mentioned for Ser392. Ser15 (Y) data is from young patients only. The standard deviations are as indicated in the chart; 𝑛 = 3.
3.2. Effect of Na-Bu, CDKi, and BAY 61-3606 Treatments on
the Site-Specific Phosphorylation of p53 Protein. Higher levels
of Ser392 phosphorylated p53 protein were found only in
the VS tumor samples from young patients of 35 years or
younger as compared to the normal WI38 cell line. Upon all
the three treatments this level reduced by approximately 3-
fold to a basal level found in WI38 cell line. A basal level
of Ser392 phosphorylated p53 protein was found in the old
patients who were above 35 years of age and the basal level
remained unaffected upon all the three treatments (Figures
1(a) and 1(b)).
Relatively higher levels of Ser15 phosphorylated p53
protein were found in all the VS tumor samples as compared
to the basal level found in WI38 cell line. The level of Ser15
p53 protein decreased by approximately 1.5- to 2-fold only
in the VS tumor tissues of young patients upon all the
three treatments. This decrease was parallel to the decrease
observed for Ser392 p53 by the same treatments. The levels
of Ser15 phosphorylated p53 protein remained unchanged by
these treatments in the VS tumor samples from older patients
who were above 35 years of age (Figures 1(a) and 1(b)).
Higher level of Ser315 phosphorylated formof p53 protein
was found only in the VS tumor tissues of the patients who
were above 35 years of age as compared to WI38 cell line and
it decreased by 2.5-fold uponNa-Bu treatment.TheCDKi and
BAY 61-3602 treatments lead to more than 3-fold decrease in
the level of Ser315 phosphorylated p53 protein.The VS tumor
tissues from the young patients showed a basal level of Ser315
phosphorylated p53 protein, similar to WI38 cell line, and it
remained unchanged upon all the three individual treatments
(Figures 1(a) and 1(b)).The decreased level of phosphorylated
p53 protein in the treated VS tumor samples as compared to
the untreated ones was statistically significant with a 𝑃 value
> 0.05.
The levels of Thr55 phosphorylated p53 proteins were
slightly higher in all the VS tumor samples as compared to
the WI38 cell line and it remained almost unaffected by all
the three individual treatments (Figures 1(a) and 1(b)).
3.3. Levels of p53 and Phospho p53 Proteins at Various Time
Intervals after Na-Bu, CDKi, and BAY 61-3606 Treatments.
Results from the time-course experiment with VS tumor
sample from young patient (VS4, 26 years) showed 1.5-fold
decrease in p53 protein level with Na-Bu treatment and 2-
fold decrease with CDKi or BAY 61-3606 treatments at 24
hours after treatment (Figures 2(a) and 2(c)). After 48 hours
a 2.5- to 3-fold decrease in the p53 protein level was found
in the treated samples. In addition, 2- to 3-fold decrease in
Ser392 (Figure 2(d)) and Ser15 (Figure 2(e)) phosphorylated
p53 protein was found 24 hours after treatment for all the
three treatments and it remained relatively unchanged 48
and 72 hours after treatments in this sample (VS4, 26 years).
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Figure 2: (a) Western blot showing level of total and phospho p53 proteins at 24, 48, and 72 hours after treatments. The sample used is from
VS4 (26 years of age). U, untreated; B, Na-Bu; C, CDKi; S, BAY 61-3606, 𝑛 = 3. (b) Western blot analysis of level of total and phospho p53
proteins at 24, 48, and 72 hours after treatment. This data is from sample number VS17 (55 years of age). U, untreated, B, Na-Bu, C, CDKi, S,
BAY 61-3606, 𝑛 = 3. (c) Histogram indicating level of total p53 protein at 24, 48, and 72 hours after treatment. This is data from sample VS4
(26 years) sample. UT, untreated; the treatments are as indicated in the figure, 𝑛 = 3. (d) Histogram indicating level of phospho Ser392 p53
protein after treatment at various time points.This data is fromVS4 (26 years old) sample. UT, untreated; the treatments are as indicated. Basal
level of Ser392 p53 protein was found in older patients of above 35 years of age and it remained unchanged with all the three treatments, 𝑛 = 3.
(e) Level of Ser15 p53 protein at various time points after treatment.This data is from VS17 (26 years old). UT, untreated; other treatments are
as shown in the figure. (f) Level of Ser315 protein after treatment at various time points. This data is from VS17 (55 years old). UT, untreated;
the other treatments are shown in figure. Basal level of Ser315 p53 protein was found in young VS patients and the level remained unchanged
upon all the three treatments.
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Figure 3: Western blot analysis of the effect of Na-Bu, CDKi, and BAY 61-3606 on the MDM2/p53 ratio in VS tumor sample 48 hours after
treatment in vitro. The Western blot analysis was done after immunoprecipitation with p53 antibody as given under Methods. The 53 kDa
p53 band and the 90 kDa MDM2 bands are as given on the left. The levels of p53 and MDM2 in the tumor lysates are in the left panel. The
MDM2/p53 ratios after immunoprecipitation are given on the right panel and the actual ratios are given below the corresponding lanes. The
MDM2/p53 ratio of WI38 was taken as 1.0 and used as a control. (a) shows data for VS sample from young patient (26 years old); (b) shows
data for VS sample from old patient (55 years old). Lane U, untreated; Lane B, Na-Bu treated; Lane C, CDKi treated; Lane S, BAY 61-3606
treated.
A basal level of Ser315 phosphorylated p53 protein was
found in VS tumor of young patient (VS4, 26 years) and
it remained unchanged with the treatments at various time
points (Figure 2(a)).
Results from the time-course experiment with VS tumor
sample from old patient of 55 years of age (VS17) showed
a 2.5- and 3-fold decrease in p53 protein level 24 hours
and 48 hours, respectively, after Na-Bu treatment and little
changewas observed between 48 and 72 hours after treatment
(Figure 2(c)). The Na-Bu treatment led to 1.5- and 2-fold
decrease of Ser315 p53 protein at 24 and 48 hours, respectively.
A 2- to 3-fold decrease of Ser315 was observed with CDKi
and BAY 61-3606 treatments and it was found early as 24
hours after treatment (Figures 2(b) and 2(f)). The levels of
Ser392 and Thr55 phosphorylated p53 protein from the VS
tumor sample of this old patient remained unchanged after
treatments (Figure 2(b)).The level of Ser15 decreased slightly
upon treatments at various time intervals and it was also
observed in samples from young patients (Figures 2(a) and
2(e)).
3.4. Effect of Na-Bu, CDKi, and BAY 61-3606 on the MDM2
Binding to p53 Protein in VS Tumor Sample. Data from
the immunoprecipitation studies showed that only a trace
amount of MDM2 was bound to p53 protein in the VS tumor
samples regardless of the age of the patients. Upon all the
three individual treatments there was a 3- to 3.5-fold increase
in the ratio of MDM2/p53. This ratio was approximately 0.5-
fold higher in the tumor tissue of young patient of 26 years of
age as compared to that of the old patient who was 55 years of
age.The normal human lung fibroblast cell lineWI38 showed
MDM2/p53 ratio of 1 (Figure 3).
4. Discussion
TheVS tumors were confirmed by routinemethods including
histopathology, MRI scan, and presence of S-100A2 marker
antigen [27, 28]. Optimum concentrations of inhibitors (1,
2, and 5mM for Na-Bu; 0.5, 1.0, and 5.0 nM for CDKi; 2, 5,
and 10 nM for BAY 61-3606) and time-dependent (24, 48, and
72 hours) expression of caspase-3 and PARP-1 cleavage were
previously analyzed and published [27, 28].
Presence of higher levels of p53 protein observed in this
study (Figures 1(a) and 1(b)) confirms our previous data on 2-
to 5- and 2- to 4-fold increase in the level of p53 mRNA and
protein, respectively, in humanVS tumors [13]. Previously we
have also reported that the levels of p53mRNA and protein in
the normal human 8th cranial nerves obtained from autopsy
cases were slightly less than that of the WI38 cell line [13].
Therefore, use of the p53 protein level in WI38 to calculate
the level in the untreated VS tumor samples is acceptable in
our experimental conditions [13] and the level of p53 protein
in the WI38 cell line was used only to estimate the p53 levels
in untreated control samples. Further comparisonswere done
between the untreated VS controls and the corresponding
treated VS tumor samples. p53 gene mutation is not reported
in human VS tumors and it was suggested that the tumor
suppressor function of the wild type p53 protein perhaps is
abrogated by other means such as modulation of its level
and its site specific phosphorylation [13]. All the VS tumor
samples used in the present study had no p53 gene mutation
[13, 27].
The current data corroborate our previous report on age-
dependent Ser392 p53 phosphorylation in the VS tumors of
young patients only (Figure 2(a)) [13]. Presence of Ser392
p53 protein is indicative of advanced tumor stage and grade
and poor prognosis and large tumor size [14, 15, 30, 31].
The MDM2 protein binds to p53, inhibits its function, and
causes its degradation [32–34].The Ser392mutants have been
reported to have reduced binding affinity to MDM2 [16].
Increased level of p53 protein in our previous report [13]
and in the present study (Figure 1(b)) is due to its decreased
binding affinity toMDM2 [16]. Conversely, the decreased p53
protein level in the treated cells observed in this study is due
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to its increased binding affinity to MDM2 and consequent
MDM2-mediated degradation (Figure 3).
Ser392 phosphorylation status was shown to influence the
phosphorylation at Ser15 [16] and our data are in agreement
with this report (Figures 2(c), 2(d), 2(e), and 2(f)). Ser15 phos-
phorylation reduced the specific activity of p53 protein as a
transcription factor in vivo [17]. In addition, thismodification
also reduced the binding affinity of p53 protein to its primary
negative regulator HDM2 [12, 16, 35].
This is the first report showing the presence of increased
level of Ser315 phosphorylation in the VS tumor samples
from old patients of 35 years and above (Figures 2(e) and
2(f)). The phosphorylation of p53 protein at Ser392 and
Ser315 sites are mutually exclusive [36, 37] and our data
is in agreement with these reports [36, 37] (Figures 1(a)
and 1(b)). Ser315 phosphorylation increases p53 transactiva-
tion potentially through nuclear retention and promotes its
MDM2 dependent proteolysis [17, 38, 39]. The observed 3-
fold increase in the p53/MDM2 binding affinity in the treated
VS sample fromold patient supports these notions (Figure 3).
Thr55 p53 is constitutively phosphorylated in unstressed
cells and dephosphorylated following stress [9, 40]. Our
data shows that the Thr55 p53 levels did not decrease upon
treatments which indicates that the treated VS tumor cells
perhaps are not reverting back to unstressed or normal state
(Figures 1(a) and 1(b)).
The function of p53 in vivo can be determined by a variety
of modifications at other phosphorylation sites in combina-
tion with modifications other than phosphorylation which
can interpret multipotency of individual modifications [10,
41]. Therefore, it is important to explore the significance of
combinations of p53 phosphorylations and perhaps other
modifications in the VS tumor cell death that we reported
previously [27, 28]. It is important to note that all the three
treatments also caused upregulation of cell death proteins
(Shh, caspase-3, and cleaved PARP) and downregulation of
key cell survival proteins (EGF-R, PI3K, NF-𝜅B, and phospho
pRb) [27, 28].
The observed cell death in the treated VS tumor samples
appears to be via activated JNK and modulation of phospho-
rylation of p53 (this study) and pRb that we reported previ-
ously [27]. In addition, other components of the p53mediated
apoptotic pathway such as increased levels of p21, caspase 3
and cleaved PARP proteins as well as DNA fragmentation
were found only in the treated samples [27, 28]. Na-Bu
induces p53 independent Fas-mediated apoptosis in cultured
MCF-7 human breast cancer cells [42]. However, the VS
tumor cells are known to undergo apoptosis that is not Fas
mediated as they lack Fas expression [43]. We found no
detectable Fas protein in 17 out of 21 VS tumor samples
(unpublished data) which is in agreement with the previously
published report by Mawrin et al. [43]. The remaining three
VS tumor samples had negligible level of Fas protein and it
remained unchanged upon Na-Bu treatment (unpublished
data). Therefore, the Na-Bu induced VS tumor cell death
observed in the present study appears to be not Fas mediated
which is in agreement with previous report [43]. The p53
protein with decreased phosphorylation in the treated VS
tumor cells could have triggered the apoptotic pathway before
it was bound to and degraded byMDM2. Many proapoptotic
indicators including increased levels of caspase-3 and p21
proteins and cleaved PARP-1 were found as early as 24 hours
after treatment [28].
Wild-type p53 is known to takemutant like conformation
and it was suggested that the function of p53 may be
regulated via its ability to adopt distinct conformations [44].
It was also suggested that phosphorylation can alter the p53
conformation and thereby its function [45, 46]. Therefore, it
is important to assess the wild-type p53 protein with altered
conformation as a drug target. It has been suggested that
novel drugs should be formulated in order to prevent tumor
development elicited by wild-type p53 protein with altered
conformation [47]. Such drugs could also be used to manage
tumors that have miss-folded wild-type p53 protein with
altered PTMs. Thus, it is important to assess the posttrans-
lational modifications (PTMs) of p53 protein especially in
tumors harbouring wild-type p53 as these PTMs can alter the
p53 protein conformation and thereby its function as a tumor
suppressor.
Na-Bu is a naturally occurring, nontoxic substance.Use of
Na-Bu as an anticancer agent has been proposed for various
tumor types [22, 24]. BAY 61-3606 [21], an anti-inflammatory
agent, is being evaluated as a cancer therapeutic considering
cancer as an inflammatory disease. CDKi and its modified
forms are also being developed as a potential cancer thera-
peutic and one such modified version was evaluated in the
cancer clinical trials [26].Therefore, we believe that the small
molecules used in this study can be developed into possible
therapeutics for managing human VS tumors. Data from
the present study shows that the p53 protein level, its site-
specific phosphorylation, and its binding affinity to MDM2
are modulated in the small molecules treated VS tumor cells
in vitro and it appears that these modulations could have
a role on VS tumor cell death caused by these molecules
[27, 28].
5. Overall Conclusion
Human VS tumors cause high morbidity. Na-Bu, modified
CDK inhibitors, and BAY 61-3606 are being evaluated for
their therapeutic potential in many human cancers. Our
data shows that these small molecules affect the level and
site-specific phosphorylation of p53 protein in vitro which
could have caused the observed cell death in vitro. It would
be interesting to evaluate the beneficial effects of these
small molecules when combined with surgical resection or
stereotactic radiosurgery which are currently used tomanage
human VS tumors.
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